Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Capital Expenditures (2022 - 2024)

Historic Capital Expenditures for Zentalis Pharmaceuticals (ZNTL) over the last 3 years, with Q2 2024 value amounting to $181000.0.

  • Zentalis Pharmaceuticals' Capital Expenditures fell 4326.02% to $181000.0 in Q2 2024 from the same period last year, while for Mar 2025 it was $181000.0, marking a year-over-year decrease of 7094.7%. This contributed to the annual value of $221000.0 for FY2024, which is 6209.26% down from last year.
  • According to the latest figures from Q2 2024, Zentalis Pharmaceuticals' Capital Expenditures is $181000.0, which was down 4326.02% from $40000.0 recorded in Q1 2024.
  • Zentalis Pharmaceuticals' 5-year Capital Expenditures high stood at $1.7 million for Q3 2022, and its period low was $40000.0 during Q1 2024.
  • Over the past 3 years, Zentalis Pharmaceuticals' median Capital Expenditures value was $181000.0 (recorded in 2024), while the average stood at $372444.4.
  • Within the past 5 years, the most significant YoY rise in Zentalis Pharmaceuticals' Capital Expenditures was 1474.82% (2023), while the steepest drop was 9451.81% (2023).
  • Quarter analysis of 3 years shows Zentalis Pharmaceuticals' Capital Expenditures stood at $160000.0 in 2022, then increased by 8.12% to $173000.0 in 2023, then grew by 4.62% to $181000.0 in 2024.
  • Its last three reported values are $181000.0 in Q2 2024, $40000.0 for Q1 2024, and $173000.0 during Q4 2023.